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Abbreviations 
ANOVA Analysis of Variance  
BMI  Body Mass Index 
CF  Cystic Fibrosis 
CFQ-R Cystic Fibrosis Questionnaire Revised  
CFTR  Cystic Fibrosis Transmembrane conductance Regulator 
CT  Computed Tomography 
ELISA  Enzyme linked immunosorbent assay 
FEV1  Forced Expiratory Volume in one second 
IL  Interleukin 
IV  Intravenous 
PWCF  Patients with cystic fibrosis 
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Abstract 
Background: Ivacaftor produces significant clinical benefit in patients with cystic fibrosis 
(CF) with the G551D mutation. Prevalence of this mutation at Cork CF Centre is 23%. This 
study assessed the impact of CFTR modulation on multiple modalities of patient assessment. 
Methods: Thirty three patients with the G551D mutation were assessed at baseline and 
prospectively three monthly for one year post initiation of ivacaftor. Change in ultra-low dose 
chest CT, blood inflammatory mediators, and sputum microbiome were assessed.  
Results: Significant improvements in FEV1, BMI and sweat chloride were observed post-
ivacaftor. Improvement in ultra-low dose CT scores were observed after treatment with 
significant mean reductions in total Bhalla score (p< 0.01), peri-bronchial thickening (p = 
0.035) and extent of mucus plugging (p< 0.001). Reductions in circulating inflammatory 
markers, including IL-1β, IL-6, and IL-8 were demonstrated. There was a 30% reduction in 
the relative abundance of Pseudomonas spp. and an increase in the relative abundance of 
bacteria associated with more stable community structures. Post-treatment community 
richness increased significantly (p = 0.03).  
Conclusions: Early and sustained improvements on ultra-low-dose CT scores suggest it may 
be a useful method of evaluating treatment response. It was paralleled improvement in 
symptoms, circulating inflammatory markers, and changes in the lung microbiota.   
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Introduction 
Ivacaftor is the first treatment which treats the underlying cause of cystic Fibrosis 
(CF) by enhancing cystic fibrosis conductance transmembrane regulatory (CFTR) function in 
the setting of class III and IV mutations (1-3).   In class III mutations, the CFTR channel is 
located at the correct site at the cell surface but fails to open and close normally.  The G551D 
mutation is the most common  class III  mutation with a worldwide prevalence of 4-5% (4). 
There is significant regional variation (5). Prevalence of the G551D mutation in Cork CF 
Centre is 23%, making it uniquely placed to offer a single centre insight on treatment 
response. Ivacaftor treatment results in significant improvement in lung function (FEV1),  
increase in body mass index (BMI), improved respiratory symptoms,  reduction in sweat 
chloride concentration, and reduction in pulmonary exacerbations in patients with CF with 
the G551D mutation (1, 2).  
Chest CT changes including mild bronchiectasis can be demonstrated in people with 
CF (PWCF) who have a normal FEV1. CT evidence of disease progression has been observed 
in individuals whose FEV1 has remained stable over time. A small study using standard CT 
protocols before and after one year of ivacaftor demonstrated improvement (6). Low dose CT 
scanning has not been used prospectively to evaluate treatment effect. We assessed the effect 
of ivacaftor on low dose chest CT.  
Microbiology studies have suggested subtle changes in the lung microbiome after 
commencement of ivacaftor (7), thus we assessed the lung microbiota after treatment. Recent 
data have demonstrated no significant change in sputum cytokines after commencement of 
ivacaftor. We assessed change in circulating inflammatory markers after treatment.  We 
hypothesis that CFTR modulatory therapy may result in improvement in low dose chest CT, 
circulating inflammatory mediators and changes in the lung microbiota.  
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Methods 
All patients with CF aged six years or older with at least one copy of the G551D mutation 
attending Cork CF centre were started on Ivacaftor post March 2013 and followed 
prospectively, for a mean period of follow-up of 12 months.  Prevalence of the G551D 
mutation at Cork CF centre is 23%, with 51 of 220 patients carrying at least one copy of the 
G551D mutation. Thirty three patients with the G551D mutation consented to participate. 
Eight children were too young to receive ivacaftor, 6 patients had already commenced 
ivacaftor either as part of a clinical trial or on a named patient (compassionate use) basis, two 
patients were post lung transplantation and three were undecided as to whether they wished to 
start treatment.  According to the UK CF trust annual report 2015, there are 32 patients with 
the G551D in Northern Ireland, representing 8% of the CF population. According to the CF 
Registry of Ireland annual report there are 93 patients with the G551D mutation in the 
Republic of Ireland, representing 11.3% of the CF population. Thus this patient group 
represents approximately one quarter of patients with the G551D mutation on the island of 
Ireland. Ethical approval was obtained for the CORK (Clinical Outcome in Real-world 
Kalydeco) study, from the Clinical Research Ethics Committee of the Cork Teaching 
Hospitals. Ivacaftor-naive patients with CF attended for assessment when clinically stable. 
Spirometry was performed according to ERS/ATS guidelines using CareFusion MicroLab™ 
spirometer which is calibrated on a regular basis (8).  Sweat-testing was performed using a 
Macroduct™ system in accordance with manufacturer’s guidelines. Modified shuttle walk 
test was performed at visits. Patients aged 14 and older completed Cystic Fibrosis 
Questionnaire Revised (CFQ-R) and for patients aged 6 -14 parents completed care-giver 
CFQ-R (9).  Participants were assessed on a three monthly basis after ivacaftor. The numbers 
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of courses of intravenous antibiotic (IV) for pulmonary exacerbations were recorded 
prospectively for 12 months after ivacaftor and compared with the number of courses of IV 
antibiotics 12 months before commencing ivacaftor.  
 
Radiology 
Adapted ultra-low dose chest CT  were performed (mean effective radiation dose 0.08 mSv), 
using a previously validated protocol (10), at baseline and after 3, 6 and 12 months of 
treatment on participants aged 16 and older. Chest CT scans were scored by consensus of two 
experienced consultant radiologists using a Bhalla scoring system (11).  
 
 
 
Sputum 
Adult patients produced a sputum sample at baseline when clinically stable, before 
commencing ivacaftor and at three monthly clinic review post ivacaftor when able to 
expectorate. 
 
Blood samples 
Blood samples were collected on all patients in bottles containing sodium citrate with the 
plasma layer separated and stored at -80 °C. Circulating inflammatory markers - including 
IL-1β, IL-6, IL-8, IL-10, TNF-α and CRP-   were measured using a multiplex enzyme linked 
immunosorbent assay (ELISA) (MesoScale Discovery (MSD) platform) according to the 
manufacturer’s guidelines (12, 13).  
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Molecular detection - Illumina MiSeq sequencing  
Processing of sputum samples and sequence library preparation is described in detail within 
the Online Supplement.  16S rRNA marker gene sequencing was performed on the Illumina 
MiSeq platform (Illumina, CA, USA) targeting the V4 the hyper-variable region of the 16S 
rRNA gene as previously described (14). Intra-sample similarities/differences were assessed 
through relative abundance changes in microbial taxa between visit time-points, sample 
richness (number of counted taxa) and diversity (Shannon Wiener Index).  
 
 
 
 
 
Statistical Analysis 
Data was analysed using SPSS version 22.0. A mean post follow up value was calculated for 
each parameter for each patient (mean of available 3, 6, 9 and 12 month values) and this post 
value was compared to the value before commencing ivacaftor. Blood inflammatory marker 
data was log10 transformed before analysis. Paired sample t test was used to evaluate mean 
change from baseline for normally distributed variables. Paired Wilcoxon signed rank test 
was used to evaluate the change in non-normally distributed data. Repeated measures 
ANOVA with a Bonferroni correction for multiple comparisons were used to compare 
changes in chest CT score. Pearson's and Spearman's Rank correlation coefficients, as 
appropriate to the distribution, were used to evaluate correlation between clinical parameters, 
blood biomarkers and chest CT scores.  
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Results 
Clinical 
Twenty adults and 13 paediatric patients participated. Table 1 summarises baseline 
characteristics. The mean age of the cohort was 21.6 years and 70% of participants were 
male. The mean baseline FEV1 % predicted was 75.21% (SD 20.7). Mean baseline sweat 
chloride was 101 mmol/l (SD 14.7). The majority (85%) of patients had the F508del mutation 
as their second mutation. One patient was homozygous for the G551D mutation. All other 
patients had a class I or II mutation as their second mutation.  
After commencement of therapy a 10.3% mean increase in FEV1 % predicted was 
observed (p<0.001) and a 58 mmol/l mean reduction in sweat chloride were observed after 
treatment (p<0.001) (Figure 1). After 1 year of treatment 83 % of patients had a sweat 
chloride below the level considered diagnostic for CF (60 mmol/l) (supplemental data e-
figure 2). No significant relationship was observed between the magnitude of change in FEV1 
and the magnitude of change in sweat chloride after 3, 6, 9 or 12 months of treatment (e-
figure 3). A 76 % reduction in pulmonary exacerbations requiring intravenous antibiotics was 
observed in the first year of therapy compared to the year before treatment; with a reduction 
in the mean number of exacerbations per patients from 0.88 to 0.21 (p=0.006) . A significant 
109 metre mean increase in modified shuttle walk test (p=0.001) and  a 1.2 kg/m2 significant 
mean increase in BMI (p<0.001) were observed after ivacaftor (Figure 2). These results are 
in keeping with those observed in previous studies (1, 7). 
A 17.5 point mean increase in adult (p<0.001) and an 8.8 point mean increase in care-
giver completed CFQ-R Respiratory Domain (p=0.08) were observed (e-Figure 4). Changes 
in other domains of the CFQ-R can be found in the online supplement (e-Table 1).   
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Radiology 
 Eighteen adults had a low dose chest CT performed before ivacaftor and after 3, 6 and 12 
months of treatment, with CT findings summarised in Table 2.  In this group a 12% mean 
increase in FEV1 % predicted (p<0.01), 58 mmol/l mean reduction in sweat chloride (p < 
0.01) and 1.6 Kg/m2 mean increase in BMI were observed. Repeat measures ANOVA 
demonstrated significant mean reductions in total Bhalla score (p < 0.01), peri-bronchial 
thickening (p = 0.035), and extent of mucus plugging (p < 0.01) with treatment. There was 
no statistically significant change in the severity and extent of bronchiectasis, number of 
bullae, emphysema, presence of sacculation or abscesses and the generations of bronchial 
divisions involved in bronchiectasis and plugging (Table 2). Post hoc testing using a 
Bonferroni correction for multiple comparisons demonstrated significant improvement from 
baseline in total Bhalla score (p < 0.01) and mucus plugging (p < 0.01) after 3, 6 and 12 
months.  E-Images 1 and 2 illustrate representative chest CT’s before and after treatment. 
 
 
Culture independent analysis 
Analysis of airway microbial community composition was performed for a subset of 
patients (n=14) who provided a sputum for pre- and at least one post-treatment sputum 
sample. For patients with more than one post-treatment sample, we analysed the last sample 
collected representing the change from baseline (pre-treatment sample). Five main taxa, 
which accounted for >1% of total sequence reads in each of the corresponding samples, 
dominated the overall community in both pre- and post-treatment sample groups (Figure 3a). 
Following treatment, there was a 30% (68% to 53%) reduction in the relative proportion of 
Pseudomonas spp. within the community. In contrast, there was an overall increase in the 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
10 
 
relative proportion of Streptococcus spp., Rothia spp., Haemophilus spp. and Prevotella spp., 
ranging from 19% to 80% post-treatment (Figure 3a). 
Taxonomic richness (i.e. the number of taxa present in a sample at a particular 
taxonomic level) increased significantly following treatment (p = 0.031; paired Student's t-
test test) (Figure 3b). We observed an increase in community diversity post-treatment but this 
did not reach statistical significance (p = 0.069; Mann-Whitney test) (Figure 3c). 
 
 
Circulating inflammatory markers  
Significant reductions in circulating log10 IL-6 (p<0.01), log10 IL-8 (p < 0.01), log10 
IL-10 (< 0.01), log10 IL-1β (p<0.01) and log10 CRP (p = 0.015) were observed after 
treatment (e-figure 6). A non-significant reduction in log10 TNF-α was observed after 
commencement of treatment (p = 0.06).  
 
 
Discussion 
This is the first study to utilise ultra-low dose chest CT (mean dose 0.08 mSv per scan) to 
serially examine the ivacaftor response over a one year period, allowing an assessment of the 
key mechanisms underlying clinical response and assessing its utility in a clinical setting to 
monitor CFTR modulatory therapy response. Significant improvements in ultra-low dose 
chest CT were observed early, after three months of treatment, with further improvements 
noted after 1 year of therapy. The greatest improvements on chest CT were in the extent of 
mucus plugging. This is in consistent with in vitro studies where ivacaftor enhanced airway 
surface liquid and ciliary beat frequency (15, 16).  The limitation of using FEV1 to assess 
treatment response in particular in patients with relatively preserved lung function is well 
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recognised (17).   Thus we suggest ultra-low dose chest CT may represent a biomarker of 
early and sustained treatment response post CFTR modulation. It may be a useful potential 
new outcome measure in clinical care with broad application across CF sites.  The growing 
awareness that patients with CF are at increased risk of certain neoplasms supports using low 
dose CT to reduce this risk (18, 19).  
 
There was no statistically significant change in bronchiectasis on chest CT after ivacaftor 
therapy in contrast to a previous smaller study which included adults and children (6). Our 
study supports that in established lung damage bronchiectasis is not reversible with CFTR 
modulatory therapy. It remains to be established if treatment with ivacaftor will delay or 
prevent the development of bronchiectasis in those who start treatment early. 
 
We observed significant improvements in lung function, weight, walk test, and CFQ-R after 
commencement of ivacaftor. The improvement in lung function was in keeping with that 
observed in the clinical trials and larger than that observed in other observational studies in 
people on treatment outside of clinical trials (7). This may be due to the fact that our cohort 
had a lower baseline FEV1 than those in other observational studies. The improvement in 
respiratory domain of the CFQ-R was larger than that observed in the clinical trials (1, 2). In 
keeping with previous work (n=24) no correlation was observed between the change in FEV1 
% predicted and change in sweat chloride at any of the time points suggesting it is a poor 
marker of treatment response (20). 
 
We have demonstrated that following ivacaftor treatment, significant changes occur in the 
microbial community composition. The reduction in the relative abundance for members of 
Pseudomonas spp. is in keeping with previous data (7). The increase in Streptococcus spp., as 
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well as in the obligate anaerobic taxa Prevotella spp. and Veillonella spp., demonstrates a 
potentially important clinical trend. The increase taxonomic richness and movement towards 
increased community diversity post-treatment is important given previous work 
demonstrating a relationship between greater lung microbial diversity and better lung 
function (21). Significant changes in the community composition of the airway microbiota in 
patients with CF have been shown to occur during the progression of the disease (22). These 
changes include the narrowing in the spectrum of bacterial taxa, associated with a reduction 
in taxonomic richness and community diversity.  The reason behind such a change in the 
community composition has been hard to elucidate and multifactorial, though increased 
patient age and antimicrobial treatment burden in chronically colonized patients (23) has been 
shown to play a significant part (21, 23). The subtle reversal towards a more "stable" 
microbiota similar to a “healthier” CF lung microbiome is important and may reflect disease 
reversal. That said a significant 76% reduction in intravenous antibiotic requirements was 
observed in the year after ivacaftor which also would contributed to this finding. Changes 
within the lung environment may alter the lung environment sufficiently to driving such 
change (24). 
 
We observed significant reduction in a number of circulating inflammatory markers. This 
‘real-world’ finding is consistent with the results from a group of patients in the clinical trials 
which demonstrated a significant reduction in circulating neutrophil count, IL-8, CRP and 
IgG after 24 weeks of treatment (25). That said another real-world cohort failed to 
demonstrate a significant change in sputum cytokines in patients with CF treated with 
ivacaftor (7). Inflammation in the CF lung is characterised by an excess influx of polymorph 
nuclear neutrophils (PMNs) (26-29). Exaggerated inflammation develops early in the course 
of CF, with elevated levels of inflammatory markers being demonstrated in the lung of 
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infants with CF in the absence of overt infection (26, 27, 30-33).   Previous studies have 
demonstrated elevated levels of circulating inflammatory markers, including IL-2, IL 6, IL-8 
and TNF-α in patients with CF compared to control cohorts (34-39) .  Similarly some studies 
have demonstrated reduction in circulating inflammatory markers after antibiotic therapy for 
pulmonary exacerbations (40). (Whether the reduction seen in our cohort is due solely to a 
decrease in pulmonary exacerbations observed in our cohort or augmented by potential 
changes in immune function post restoration of CFTR function remains to be evaluated given 
that studies have demonstrated improved neutrophil function after ivacaftor therapy (41, 42).  
Given the sustained improvements in chest CT observed from 3 months after 
commencement of ivacaftor - in particular improved mucus plugging and peri-bronchial 
thickening we suggest that enhanced mucus clearance is a key mechanism underlying the 
increase in lung function and reduction in pulmonary exacerbations observed in patients 
treated with ivacaftor. This is consistent with in vitro studies where ivacaftor resulted in 
improved airway surface liquid and ciliary beat frequency (15, 16).   
The subsequent improvement in symptoms, reduction in circulating inflammatory 
markers, and subtle changes in the lung microbiome are likely secondary factors contributing 
to this improvement. 
 
Limitations  
 
A limitation of this study is that it is observational in nature without a control group who did 
not receive ivacaftor treatment. However, the benefits of ivacaftor relative to placebo have 
been well demonstrated in existing trials, the observed improvements are similar to those 
reported in the above trials and would be disproportionate to changes expected in untreated 
cohort.  We avoided recruitment sample related variability given that we included the entire 
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cohort of patients attending our designated referral centre for the region.  All eligible patients 
received the drug as it was funded by the state and not dependant on health insurance status. 
 
Conclusion  
This study demonstrates sustained improvement after ivacaftor across multiple modalities of 
assessment including multiple clinical parameters, ultra-low dose chest CT, blood 
inflammatory markers and lung microbiome. It suggests the potential utility of ultra-low dose 
chest CT as an approach for assessing treatment response.   
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Table 1. Baseline Characteristics 
 Mean (SD) 
N = 33 
Gender (% male) 70 
Age (years) 21.6 
FEV1 (% predicted) 75.21 (20.7) 
Weight (Kg) 51.26 (19.7) 
Walk test (metres) 1002 (320) 
Sweat test (mmol/l) 101 (14.7) 
Mutation (%)  
  G551D/F508del 85% 
  G551D/G551D 3% 
  G551D/3028delA 3% 
  G551d/1717-1G A 3% 
  G551D/E56K 3% 
  G551D/R553x 3% 
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Table 2. Chest CT Bhalla Score 
Bhalla score (range) Baseline 
 Mean score 
(SD) 
N = 18 
3 months 
 Mean 
score (SD) 
N = 18 
6 months 
Mean score 
(SD) 
N = 18 
12 months 
Mean score 
(SD) 
N = 18 
P value 
Total Bhalla score (0-
25) 
12.56 (4.2) 10.94 (3.6) 10.22 (3.4) 10.33 (3.4) <0.01 
Peri-bronchial 
thickening (0-3) 
1.11 (0.8) 0.89 (0.7) 0.83 (0.7) 0.72 (0.6) 0.035 
Severity of 
bronchiectasis (0-3) 
2.06 (0.9) 2.11 (0.9)  2.06 (0.9) 2.06 (0.9) 0.33 
Extent of 
bronchiectasis 
2.83 (0.4) 2.83 (0.4) 2.78 (0.4) 2.83 (0.4) <0.01 
Sacculation or 
abscesses (0-3_ 
0 (0) 0 (0) 0 (0) 0 (0) 1 
Generations of 
brochial divisions 
involved (0-3) 
2.44 (0.7) 2.4 (0.8) 2.44 (0.7) 2.4 (0.8)  0.7 
Number of bullae (0-
3) 
0.67 (1.1) 0.5 (0.9) 0.5 (0.9) 0.44 (0.9) 0.3 
Emphysema (0-2) 1.17 (0.7) 0.94 (0.7) 0.7 (0.6) 1.0 (0.6) 0.15 
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Collapse/consolidation 
(0-2) 
0.44 (0.6) 0.28 (0.6) 0.22 (0.4) 0.22 (0.4) 0.1 
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Figure 1 Change in FEV1 % predicted and sweat chloride concentration at baseline and 
after 1 year of ivacaftor therapy 
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Figure 2 Change in BMI and modified shuttle walk test after ivacaftor 
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Figure 3 (a) Stacked bar representing the relative abundance of genera accounting for 
the total sequence count in each group, (b) taxonomic richness and (c) Shannon Wiener 
Index of diversity. The top and bottom boundaries of each box indicate 75th and 25th 
quartile values, respectively, with the blue line inside each box representing the median
(50th quartile). The ends of the whiskers indicate the 95% CI around the median. 
Difference between normally distributed variables (richness) was evaluated using a 
paired t-test. Difference between non-normally distributed variables (Shannon Wiener 
diversity) was assessed using Mann-Whitney test. P < 0.05 denotes statistical 
significance. 
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e-Appendix 1. 
Radiology  
CT technique and image reconstruction 
All studies were acquired using a 64-slice multidetector CT scanner (General Electric 
Discovery CT 750 HD; GE Healthcare, GE Medical Systems, Milwaukee, WI, USA) without 
intravenous contrast material.  
 
7-section low-dose protocol 
A modified 7-section, low-dose axial CT protocol previously validated at our institution was 
used for the pre-treatment and first 12-month quarterly studies.17 
Single anteroposterior and mediolateral localizer radiographs were used to identify 5 levels, 
evenly spaced, at which images were acquired. Images were obtained with the patient at 
end-inspiration through the lung apices, aortopulmonary window, carina, and at the widest 
cardiac and thoracic diameters. 2 further images were obtained with the patient in full 
expiration at the aortopulmonary window and at the widest cardiac diameter. The following 
parameters were used: tube voltage of 120 kV; gantry rotation time of 0.4 seconds; field of 
view (FOV) of 32cm; and z-axis automatic tube current modulation with minimum and 
maximum tube current thresholds set at 10 and 100 mA with a tolerated noise index of 
29HU. Images were acquired at each of the 7 levels at a slice thickness of 0.625mm and 
reconstructed to a slice thickness of 1.25 mm with the standard departmental protocol 
employing hybrid IR: 70% filtered back projection and 30% adaptive statistical iterative 
reconstruction (ASIR)(GE Healthcare, GE Medical Systems, Milwaukee, USA). 
 
Full-volume low-dose protocol 
A low-dose volumetric protocol was used to acquire the 24-month surveillance CT. the 
following technical parameters in combination with model-based iterative reconstruction 
(MBIR); Veo (GE Healthcare, GE Medical Systems, Milwaukee, USA) were used: tube 
voltage of 80 kV; tube current of 20mA; gantry rotation time of 0.4 seconds; pitch factor of 
1.375; and FOV of 32cm.  
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Scanning was performed at end-inspiration from the lung apices to the bases, including the 
costophrenic recesses. No additional expiratory phase imaging was performed.  Images 
were acquired at a slice thickness of 0.625mm and reconstructed at a final slice thickness of 
1.25 mm. 
 
Quantification of lung disease 
Disease severity was scored independently by two readers (MMM and OJOC) using a 
validated scoring system (Bhalla score).  Both readers had significant prior experience of 
MBIR-reconstructed images. To minimize the effects of recall bias, all datasets were 
anonymized and reviewed in a random order. In addition, a 6-week delay was instituted 
between the review of the baseline and 1-year LD-ASIR studies and the 2-year LD-MBIR 
studies. Images were reviewed on lung window settings (window width, 1500HU; window 
level: -500HU) on the picture archiving and communication system using axial reformations 
(Impax 6.5.3; Agfa healthcare, Morstel, Belgium). 
The presence and severity of 9 morphological changes were evaluated including: severity of 
bronchiectasis; peribronchial thickening; extent of bronchiectasis (number of 
bronchopulmonary segments); extent of mucus plugging (number of lung segments); 
abscesses or sacculations (number of lung segments); generations of the bronchial divisions 
involved; number of bullae; air trapping (number of lung segments); and 
collapse/consolidation. A score of 0 to 3 (0: absent; 1: mild; 2: moderate; 3: severe) was 
assigned to each category to give a total score ranging from 0 to 25. A score of 0 indicated 
that no abnormality was detected. 
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e-Figure 1. Interval resolution of right middle lobe medial segmental consolidation 
and collapse and reduction in the degree of peribronchial wall thickening and  foci 
of mucous plugging in the left and right  lower lobes. Persistent residual mucous 
plugging in the lingula anteriorly. 
 
e-Figure 2. Interval reduction in degree of peribronchial wall thickening, mucous 
plugging  and tree in bud opacification, with the degree of bronchiectasis 
remaining unchanged. 
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Blood inflammatory mediators 
Blood samples were diluted 1:1 with PBS and separated using a ficoll banding. The plasma 
was frozen immediately at -80°C. Plasma samples were subsequently thawed on ice. 
Circulating inflammatory mediators were measured using a mesoscale discovery (MSD) 
platform in keeping with manufacturer’s guidelines.  
 
Sputum Microbiome 
Sputum processing for microbiological analysis 
Frozen sputum samples were thawed and any sputum plugs were separated from any saliva 
like material for analysis. For pre-lysis of sputum plugs transfer ~100mg of sputum plugs to 
a sterile Eppendorf tube and mixed with an equal volume of 10% dithiothreitol (DTT, 
Sputolysin®, Calbiochem, CA, USA). Each sample was mixed by vigorous vortexing and 
incubated at room temperature (R°T) for 30 minutes on a thermo-shaker at 2000 RMP.  
Next add 200 µl lysis buffer (5 mg/mL lysozyme in BLB [Roche Bacteria Lysis Buffer]), 
vortex thoroughly and incubate for 30 minutes at 37°C in an orbital thermo-shaker at 2000 
RMP. Transfer the total volume to a glass bead tubes (matrix A) and homogenize on the 
FastPrep®-24 instrument (MP Biomedical, CA, USA) at speed setting 6.0 for 40 seconds. 
Remove the sample tubes from the FastPrep®-24 instrument and centrifuge at 13,000 x g 
for 1 minute. To the homogenized sample add 32 µl of proteinase K (20 mg/mL, Qiagen, 
Hilden, Germany) and mix thoroughly by vortexing. Incubate at 65°C for 10 minutes on a 
heated thermo-shaker at 1500 RMP.  Next add 150µl of nuclease free water, place the tube 
in the FastPrep®-24 instrument (MP Biomedical, CA, USA) and homogenize at speed setting 
6.0 for 40 seconds. Incubate the homogenized sample at 95°C for 10 minutes on a heated 
thermo-shaker at 1000 RMP. Finally, centrifuge at 10,000 x g for 10 minutes at 4°C and 
transfer 200 µl to a sterile Eppendorf tube for storing at -80°C until further use. 
 
Extraction of gDNA from sputum samples 
Pre-lysed samples were extracted on the Roche MagNA Pure extraction system (Roche 
Diagnostics Limited, West Sussex, UK) according to manufacturer's instructions. 
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Library preparation for the Illumina MiSeq amplicon sequencing 
Sample processing and library generation was performed as previously described by 
Lundberg et al. (1) Briefly, the library generation was as follows: PCR 1: Pre-amplification of 
16S rRNA marker gene region is necessary for potentially low biomass template in order to 
carry enough tagged amplicon through to the final indexing-amplication steps. Perform PCR 
using ~200 ng of gDNA from each sample. Using non-modified primers targeting positions 
515F and 806R within the V4 region of the 16S rRNA marker gene prepare a mastermix 
solution [5µl 5x Phusion Hifi Buffer, 0.5µl (10 mM) dNTP, 1 µl (10 µM) V4 primer mix; 0.25 
µl Phusion HS II polymerase and make to 25 µl per reaction using DEPC water] and amplify 
using the following condition: 98°C for 30 seconds (x1) à98°C for 10 seconds + 52°C for 30 
seconds + 72°C for 20 seconds (10 cycles) à72°C for 5 minutes àhold at 4°C for ¥. Next 
clean-up the PCR products from PCR 1 using AxyPrep Mag PCR Clean-up kit as follows; 
vortex magnetic beads well before use to resuspend any magnetic beads that may have 
settled. Aliquot 15 µl of Axygen beads to 10 µl of PCR product into a sterile 96 well plate. 
Mix well by repeated pipetting and incubate at R°T for 5 minutes. Place the reaction plate 
onto the IMAG magnetic separation device and wait until the liquid turns clear. Remove the 
clear liquid from the plate and discard. Next add 180 µl of 70% EtOH to each well of the 
reaction plate and incubate for 30 seconds at R°T. Remove the 70% EtOH from each well 
and discard. Repeat the previous step once. Air dry the beads at R°T for no more than 5 
minutes and be careful not to over dry the magnetic beads as this will cause the beads to 
crack and lead to decreased elution efficiency. Ensure that all the ethanol has been removed 
from each well. Add 11 µl of molecular grade H2O to each well. Remove reaction plate from 
the IMAG separation device and mix well by gentle vortexing. Place the reaction plate onto 
the IMAG separation device for 1 minute to separate the beads from the solution. Transfer 
10 µl of the cleaned up PCR product to a sterile 96 well plate for the next PCR step. PCR 2: 
Reverse Tagging Step using the cleaned product from PCR 1 using equimolar mixture of the 
reverse frame-shift (FS) primers 808R_f1, 808R_f2, 808R_f3, 808R_f4, 808R_f5, 808R_f6). 
Primers are combined into a working stock of 0.5 µM. Perform 1 cycle PCR using 10µl of 
product from PCR 1. Prepare a mastermix solution [5 µl 5x Phusion Hifi Buffer, 0.5 µl (10 
mM) dNTP, 2 µl (0.5 µM, Reverse_MT_tag Primer mix); 0.25 µl Phusion HS II polymerase 
and 7.25 µl DEPC water] and amplify using the following condition: 98°C for 60 seconds 
(x1) à98°C for 10 seconds + 50°C for 30 seconds + 72°C for 60 seconds (1 cycle) à hold at 
4°C for ¥. Next clean-up the PCR products from PCR 1 using AxyPrep Mag PCR Clean-up kit 
as follows; vortex magnetic beads well before use to resuspend any magnetic beads that 
may have settled. Aliquot 15 µl of Axygen beads to 10 µl of PCR product into a sterile 96 
well plate. Mix well by repeated pipetting and incubate at R°T for 5 minutes. Place the 
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reaction plate onto the IMAG magnetic separation device and wait until the liquid goes clear. 
Remove the clear liquid from the plate and discard. Next add 180µl of 70% EtOH to each 
well of the reaction plate and incubate for 30 seconds at R°T. Remove the 70% EtOH from 
each well and discard. Repeat the previous step once. Air dry the beads at R°T for no more 
than 5 minutes and be careful not to over dry the magnetic beads as this will cause the 
beads to crack and lead to decreased elution efficiency. Ensure that all the ethanol has been 
removed from each well. Add 11 µl of DECP water to each well. Remove reaction plate from 
the IMAG separation device and mix well by gentle vortexing. Place the reaction plate onto 
the IMAG separation device for 1 minute to separate the beads from the solution. Transfer 
10 µl of the cleaned up PCR product to a sterile 96 well plate for the next PCR step.  PCR 3: 
Forward-Tagging Step using the cleaned product from PCR 2 using equimolar mixture of the 
forward frame-shift (FS) primers 515F_f1, 515F _f2, 515F _f3, 515F _f4, 515F _f5, 515F 
_f6). Primers are combined into a working stock of 0.5 µM. Perform 1 cycle PCR using 10µl 
of product from PCR 2. Prepare a mastermix solution [5 µl 5x Phusion Hifi Buffer, 0.5 µl (10 
mM) dNTP, 2 µl (0.5 µM, Reverse_MT_tag Primer mix); 0.25 µl Phusion HS II polymerase 
and 7.25 µl DEPC water] and amplify using the following condition: 98°C for 60 seconds 
(x1) à98°C for 10 seconds + 50°C for 30 seconds + 72°C for 60 seconds (1 cycle) à hold at 
4°C for ¥. Next clean-up the PCR products from PCR 3 using AxyPrep Mag PCR Clean-up kit 
as follows; vortex magnetic beads well before use to resuspend any magnetic beads that 
may have settled. Aliquot 17.5 µl of Axygen beads to 10 µl of PCR product into a sterile 96 
well plate. Mix well and incubate at R°T for 5 minutes. Next place the reaction plate onto 
the IMAG magnetic separation device and wait until the liquid goes clear. Remove the clear 
liquid from the plate and discard. Add 180 µl of 70% EtOH to each well of the reaction plate 
and incubate for 30 seconds at R°T. Remove the 70% EtOH from each well and discard. 
Repeat previous step once. Air dry the beads at R°T for no more than 5 minutes, be careful 
not to over dry the magnetic beads as this will cause the beads to crack and lead to 
decreased elution efficiency. Ensure that all the ethanol has been removed from each well. 
Add 16 µl of DEPC water to each well and remove the reaction plate from the IMAG 
magnetic separation device and mix well to resuspend the magnetic beads. Next place the 
reaction plate onto the IMAG separation device for 1 minute to separate the beads from the 
solution. Transfer 15 µl of the cleaned up PCR product to a sterile 96 well plate for the next 
PCR step.  PCR 4: Nextera-Adapter/Indexing Amplification step by performing a 34 cycle 
PCR, targeting the V4 region of the 16S rRNA marker gene, using 15 µl of the cleaned 
reverse and forward tagged product from step PCR 3. Each reaction will have the same 
forward primers and a unique reverse primer which acts as the index (barcode) for each 
sample. The forward and reverse primers are typically diluted to a working stock of 5 µM 
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and can be added separately to each reaction (the forward primer is universal and could be 
added to any master-mixes instead), or the forward primer can be added to each reverse 
primer in a working stock in a plate for further use. Prepare a mastermix solution [10 µl 5x 
Phusion Hifi Buffer, 1µl (10 mM) dNTP, 2.5 µl forward primer (SEQ_V4_F; 
AATGATACGGCGACCACCGAGATCTACACGCCTCCCTCGCGCCATCAGAGATGTG); 2.5µl reverse 
primer (INDEX_R_bc1 to bc96; CAAGCAGAAGACGGCATACGAGAT XXXXXXXX 
GTGACTGGAGTTCAGACGTGTGCTC); 0.5 µl Phusion HS II polymerase and 7.25 µl DEPC 
water] and amplify using the following condition: 98°C for 30 seconds (x1) à98°C for 10 
seconds + 63°C for 30 seconds + 72°C for 30 seconds (34 cycle) àhold at 4°C for ¥. Next 
run 5 µl of each reaction on a 1% agarose gel to visually confirm presence of products 
(~453bp). Clean the PCR products from step PCR 4 with AxyPrep Mag PCR Clean-up kit as 
follows; vortex magnetic beads well before use to resuspend any magnetic beads that may 
have settled. Aliquot 35 µl of Axygen beads and the entire PCR product into a sterile 96 well 
plate and mix well and incubate at R°T for 5 minutes. Next place the reaction plate onto the 
IMAG magnetic separation device and wait until the liquid goes clear. Remove the clear 
liquid from the plate and discard. Add 180 µl of 70% EtOH to each well of the reaction plate 
and incubate for 30 seconds at R°T. Remove the 70% EtOH from each well and discard. 
Repeat the previous step once. Air dry the beads at R°T for no more than 5 minutes, 
avoiding to not over drying the magnetic beads as this will cause the beads to crack and 
lead to decreased elution efficiency. Next add 50 µl of DEPC water to each well and remove 
reaction plate from the IMAG magnetic separation device and mix well. Place the reaction 
plate back onto the IMAG magnetic separation device for 1 minute to separate the beads 
from the solution. Transfer all of the cleaned up PCR product to a sterile 96 well plate. Next 
quantify products using Quant-iT™ PicoGreen® dsDNA Assay kit (Life Technologies, Paisley, 
UK) in a 96 well plate using 2 µl of cleaned product. Pool equimolar amounts from each 
sample adding no more than 20 µl of each reaction to the final pool. Typically, only 
reactions that failed will need to be added at this volume (the pool will not be equimolar for 
them). Gel purify the pool by running it on a 1% agarose gel and gel extracting the correct 
size band (~453bp) using the QIAEX II kit (Qiagen, Manchester,UK) according to 
manufactures instructions, removing as much of the excess agarose gel as possible. The 
final sample pool was quantified in triplicate using the Quant-iT™ PicoGreen® dsDNA Assay 
kit (Life Technologies, Paisley, UK) and the concentration converted to nM (minimum 4 nM 
required). Samples were stored at -20ᵒC/-80ᵒC until submission for Illumina MiSeq 
sequencing. 
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Molecular detection - Illumina MiSeq data processing 
Paired-end Illumina MiSeq sequences were processed using QIIME (Quantitative Insights 
into Microbial Ecology; version 1.8.0), (2) by joining the corresponding paired-end reads, 
removing the Illumina adapters and barcode sequences.  We removed sequences with 
length less than 200 and longer than 400 nucleotides, as well as sequences with an average 
quality score (Phred score) of <Q30. Sequences lacking an exact match to a 5' primer were 
also removed from the dataset along with sequences that contained any mismatches in the 
barcode sequence. Following this initial processing step, we removed potential chimeric 
sequences from downstream processing through the implementation of Chimera Slayer. (3) 
Sequences were then clustered into their representative OTUs based on the 97% sequence 
identity using the UCLUST algorithm, (4) aligned against full length 16S rRNA marker gene 
sequences from the Greengenes reference alignment (version 13.8) by PyNAST (5) and 
assigned their taxonomic identities according to the Ribosomal Database Project Classifier 
Tool (v 2.2) (6) using a open reference OTU picking as implemented within QIIME. A 
number of taxa were detected in the background of the negative control, however this 
community lacked a strong dominance by any single taxon. Futhermore, singletons (i.e. 
taxa represented by a single read over all the samples) and OTUs representing potential 
human sequences, Archaea , Cyanobacteria, unassigned OTUs and those found in the 
background of the negative control were filtered out and treated as contaminating 
sequences prior to all downstream analysis. The resulting dataset was then converted to a 
final quality filtered OTU table and presented either normalised absolute counts or relative 
abundance. 
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Supplemental Results   
e-Figure 3. Mean Liver Function Test before and after treatment. 
 
 
 
e-Figure 4. Percentage of patients in each sweat chloride category. 
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e-Figure 5. Relationship between change in FEV1 (% predicted) and change in 
sweat chloride (mmol/l). 
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Change in Adult and Paediatric CFQ-R after commencement of ivacaftor 
e-Table 1 Adult CFQ-R (N = 20) 
CFQ-R Domain Mean baseline score 
(SD) 
Mean change 
(SD) 
P value 
Eating 92.78 (15.8) 2.036 (8.7) 0.312 
Physical 86 (17.6) 4.35 (12.6) 0.139 
Vitality 66.25 (15.87) 5.5 (13.5) 0.082 
Emotion 79.76 (15.6) 2.4 (7.88) 0.188 
Treatment 
burden 
67.24 (18.56) 5.6 (14.9) 0.109 
Health 
perception 
74.46 (19.78) 6.1 (18.7) 0.161 
Social 78.33 (14.95) 0.88 (12.78) 0.761 
Body Image 69.46 (25.21) 8.8 (22.17) 0.092 
Role 86.26 (18.2) 1.66 (8.66) 0.402 
Weight 58.34 (37.27) 22.63 (31.22) 0.004 
Digestive 86.12 (16.69) 3.06 (10.78) 0.22 
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e-Figure 6. Change in CFQ-R respiratory domain. 
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e-Table 2 Parent/care-giver CFQ-R (N = 11) 
CFQ-R Domain Mean baseline score 
(SD) 
Mean change 
(SD) 
P value 
Physical 94.96 (5.6) 1.74 (8.42) 0.489 
Emotion 85.5 (12.3) 1.26 (12.79) 0.739 
Vitality 73.3 (17.75) 1.11 (10.67) 0.725 
School 78.73 (17.36) 2.38 (13.3) 0.548 
Eating 86.11 (18.57) -0.236 (19.26) 0.967 
Body Image 75.9 (28.76) 13.73 (18.65) 0.027 
Treatment 
Burden 
62.97 (21.38) -2.0 (17.5) 0.7 
Health 
perception 
84.28 (12.9) -0.7 (18.69) 0.899 
Digestive 80.58 (16.48) 7.7 (15.5) 0.113 
Weight 63.89 (33.22) 21.76 (33) 0.043 
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